(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 July 2013 (11.07.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/103384 A1

(51) **International Patent Classification**:
A61K 31/155 (2006.01) *A61K 31/341* (2006.01)
A61K 31/343 (2006.01) *A61K 31/41* (2006.01)
A61K 31/36 (2006.01) *A61K 31/53* (2006.01)
A61K 31/381 (2006.01) *A61P 3/00* (2006.01)
A61K 31/40 (2006.01)

(21) **International Application Number**:
PCT/US2012/046335

(22) **International Filing Date**:
11 July 2012 (11.07.2012)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
PCT/US2012/020548
6 January 2012 (06.01.2012) US
13/345,135 6 January 2012 (06.01.2012) US
61/649,171 18 May 2012 (18.05.2012) US

(71) **Applicant** *(for all designated States except US)*: **ELCELYX THERAPEUTICS, INC.** [US/US]; 11995 El Camino Real, Ste 305, San Diego, CA 92130 (US).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **BARON, Alain, D.** [US/US]; 12863 Baywind Point, San Diego, CA 92130 (US). **FINEMAN, Mark, S.** [US/US]; 12444 Oakfort Place, San Diego, CA 92131 (US). **BEELEY, Nigel, R. A.** [US/US]; 227 Loma Corte Drive, Solana Beach, CA 92075 (US).

(74) **Agent**: **LORENZ, Todd**; Arnold & Porter LLP, Three Embarcadero Center, 7th Floor, San Francisco, CA 94111 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2013/103384 A1

(54) **Title**: BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS

(57) **Abstract**: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.